Hebei Changshan Biochemical Hits Day High with 8.87% Surge

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has experienced a significant surge in its stock price, gaining 8.87% on February 25, 2026. The stock reached an intraday high of CNY 49.49, marking a notable performance against the backdrop of the China Shanghai Composite, which declined by 1.26% on the same day. Over the past week, Hebei Changshan has shown an 8.01% increase, contrasting with the Shanghai Composite's modest gain of 0.41%. However, the company's performance over the past month reflects a decline of 17.64%, while its year-to-date performance stands at a decrease of 24.91%. In a longer-term view, the stock has demonstrated impressive growth, with a remarkable 127.8% increase over the past year and a staggering 706.75% rise over the last three years. Despite these gains, the company faces challenges, including a high debt-to-equity ratio of 1.54 and a negative return on equity of -19.33%. The pharmaceutical and biotechnology sector remains competitive, and Hebei Changshan's financial metrics indicate a complex landscape as it navigates its market position.